Crescent Biopharma, Inc. (CBIO) Key Metrics
CBIO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $439.8M
- Enterprise value
- $361.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 37.0
- Price / book
- 3.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
CBIO key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCBIO returns How much profit the business earns on the capital it uses.
CBIO financial health Debt, liquidity and how easily interest is covered.
CBIO efficiency & capital use Working capital cycle and where the cash goes.
CBIO valuation history
CBIO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CBIO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CBIO cash returned to shareholders
CBIO price vs earnings per share
CBIO key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $123.5M | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$88.0M | — | — | — | — | — | — | — | — | — |
| Price / sales | 11.4 | — | — | — | — | — | — | — | — | — |
| Price / book | 0.6 | — | — | — | — | — | — | — | — | — |
| EV / sales | -8.1 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −124.6% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −117.0% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.1% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $11.86 | $25.00 | $236.00 | $303.00 | $144.00 | $376.00 | $529.00 | $947.00 | $1,679.00 | $610.00 |
| Per share | ||||||||||
| Revenue per share | $1.04 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$14.78 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$6.87 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$13.87 | — | — | — | — | — | — | — | — | — |
| Cash per share | $20.47 | — | — | — | — | — | — | — | — | — |
| Book value per share | $19.49 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $19.04 | — | — | — | — | — | — | — | — | — |
| Capex per share | $7.00 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.16 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 10.4M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −164.2% | — | −90.7% | −75.0% | −60.5% | −36.1% | −30.1% | −29.7% | −42.9% | −84.0% |
| Return on assets (ROA) | −111.6% | −119.9% | −76.0% | −63.9% | −53.5% | −32.8% | −28.3% | −28.1% | −38.9% | −70.0% |
| Return on tangible assets | −65.3% | −136.2% | −81.4% | −90.1% | −67.2% | −35.7% | −32.2% | −22.5% | −25.9% | −75.0% |
| Free cash flow margin | — | — | — | — | — | −386.8% | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.6M | $37.5M | $808,402 | $918,555 | $1.9M | $2.8M | $3.6M | — | — | — |
| Cash & short-term investments | $213.2M | $34.8M | $41.8M | $47.9M | $90.3M | $137.0M | $158.2M | $209.9M | $123.9M | $40.0M |
| Net debt | −$211.5M | $2.7M | −$41.0M | −$47.0M | −$88.3M | −$134.2M | −$154.6M | −$209.9M | −$123.9M | −$40.0M |
| Debt / equity | 0.01 | — | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | — | — | — |
| Debt / assets | 0.01 | 1.05 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | — | — | — |
| Current ratio | 6.56 | 3.62 | 6.41 | 5.71 | 7.68 | 11.13 | 14.84 | 24.22 | 15.56 | 6.40 |
| Quick ratio | 6.56 | 3.62 | 6.41 | 5.71 | 7.68 | 11.13 | 14.84 | 24.22 | 15.56 | 6.37 |
| Interest coverage | -69.9 | -58.6 | — | — | — | — | — | — | — | — |
| Working capital | $200.6M | $25.2M | $37.0M | $41.8M | $79.0M | $125.8M | $151.6M | $203.5M | $119.0M | $34.2M |
| Invested capital | −$8.5M | −$12.8M | −$2.6M | −$4.0M | −$6.7M | −$6.0M | −$378,212 | −$4.5M | −$4.2M | −$4.7M |
| Tangible asset value | $198.3M | −$15.5M | $38.4M | $42.9M | $81.6M | $128.2M | $154.2M | $205.5M | $119.7M | $35.3M |
| Net current asset value | $199.4M | −$16.3M | $36.9M | $41.8M | $78.0M | $123.7M | $148.8M | $202.9M | $118.3M | $33.4M |
| Graham net-net per share | $18.19 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $177,000 | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 672.4% | — | 213.9% | 112.3% | 1.3% | 0.7% | — | — | — | 3,806.5% |
| Capex / depreciation | 868.08 | 0.28 | 0.14 | 0.41 | 0.06 | 0.25 | 0.16 | 0.46 | 1.12 | 3.70 |
| Stock-based compensation / revenue | 122.6% | — | 35,604.8% | 5,143.4% | 524.9% | 67.9% | — | — | — | 16,025.8% |
| R&D / revenue | 1,273.4% | — | 200,716.6% | 37,854.5% | 4,094.9% | 442.1% | — | — | — | 125,847.7% |
| SG&A / revenue | 234.1% | — | 192,130.0% | 25,449.3% | 1,475.8% | 164.7% | — | — | — | 46,757.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 305.2 | — | 5,837.0 | 353.7 | 0.6 | 3.4 | — | — | — | 3,031.9 |
| Days of inventory on hand | — | — | — | — | — | — | — | -0.5 | — | — |
| Days payables outstanding | 21,952.1 | 5,059.4 | 2,188.4 | 544.2 | — | 676.1 | 831.9 | 3,522.8 | 2,917.0 | — |
| Cash conversion cycle (days) | -21,646.9 | — | 3,648.6 | -190.5 | — | -672.8 | — | — | — | — |
| Receivables turnover | 1.20 | 0.00 | 0.06 | 1.03 | 663.48 | 108.06 | 0.00 | 0.00 | 0.00 | 0.12 |
| Payables turnover | 0.02 | 0.07 | 0.17 | 0.67 | 0.00 | 0.54 | 0.44 | 0.10 | 0.13 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | — | — | 0.00 |
| Asset turnover | 0.08 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $9.1M | $156,200 | $159,918 | $72,682 | $1,748 | $94,051 | $299,538 | $257,538 | $185,307 | $153,671 |
| Average payables | $5.1M | $487,558 | $919,153 | $1.5M | $2.1M | $1.8M | $2.0M | $2.7M | $2.1M | $1.1M |
| Average inventory | — | — | — | — | — | — | — | −$405 | — | $198,836 |
| Intangibles / total assets | 2.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CBIO's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CBIO valuation and financial ratios
Crescent Biopharma earned a return on equity of −164.2% in fiscal 2025. It ended the year with $1.6 million of debt and $213.2 million in cash and short-term investments, a net cash position of $211.5 million. It returned $0.2 million to shareholders: $0 in dividends and $0.2 million in share buybacks.
See the CBIO income statement, the CBIO chart for price history, or the CBIO stock overview for the latest quote and news.
CBIO key metrics FAQ
What is Crescent Biopharma's return on equity?
Crescent Biopharma's return on equity (ROE) was −164.2% in fiscal 2025: net income of -$153.9 million on average shareholders' equity of $93.8 million.
How much debt does Crescent Biopharma have?
Crescent Biopharma had total debt of $1.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
Does Crescent Biopharma buy back its shares?
Yes. Crescent Biopharma spent $0.2 million on net share repurchases in fiscal 2025.
What is Crescent Biopharma's free cash flow yield?
Crescent Biopharma generated -$144.5 million of free cash flow in fiscal 2025, a free cash flow yield of −117.0% on its market value at year-end ($123.5 million).
What is Crescent Biopharma's current ratio?
Crescent Biopharma's current ratio was 6.56 at the end of fiscal 2025: current assets were 6.56 times current liabilities.